The Washington PostDemocracy Dies in Darkness

Faster Progress Is Needed on Treatments for Long Covid

Can the coronavirus lurk long after an infection?
Can the coronavirus lurk long after an infection? (Photographer: CDC/Getty Images)
Placeholder while article actions load

Long Covid is making it hard for millions of Americans to return to normal life, pushing some out of the workforce altogether, sometimes permanently. Yet medical efforts to figure out how best to help these patients are proceeding only slowly.

Research has zeroed in on a few probable causes of long Covid, perhaps the most intriguing of which is the idea that the coronavirus sometimes lingers in the body undetected for months after an initial infection. The theories should not be difficult to investigate, and the National Institutes of Health has $1.2 billion to spend on the work. But it’s not moving fast enough.

The slow-footed response to long Covid is often attributed to the nebulous nature of the problem. Symptoms are so numerous as to seem almost random. One large UK study counted as many as 200 distinct health effects across 10 different organs. Duration varies, too; for some patients, the symptoms last only a month or two, while others seem to never fully recover. Even estimates of how many people suffer vary widely. The U.S. Government Accountability Office pegs the long-Covid population at anywhere from 7.7 million to 23 million. The Centers for Disease Control and Prevention finds that one in five Americans has experienced post-infection symptoms.

Categorizing all these cases based on their underlying biology will take time. And it will remain difficult to distinguish long Covid from other conditions.

But researchers can make progress toward helping patients before they have nailed down a neat and tidy explanation for the condition. Already, scientists have several good hypotheses about how to treat the problem, and ideas for preventing it in the first place. And some of these theories can be tested, even without inventing new drugs.

Consider, for example, the theory that persistent lurking virus poses problems, for example, by prompting the immune system to react.

A growing body of research offers support to this theory. In one recent study of blood samples taken from people with long Covid, researchers detected coronavirus spike proteins over the course of several months in 60% of patients. In some of them, the bits of virus could be measured for as far out as a year. Because humans have enzymes that quickly chew up the spike protein in the bloodstream, finding protein pieces over time points to some kind of viral reservoir, says David R. Walt, the Harvard professor who led the research.

This study has yet to undergo peer review, but Walt, who was the scientific founder of the gene-sequencing company Illumina, says it has generated more initial interest than any paper he’s put out in his career. The enthusiasm is helping his team access blood samples that have been collected over longer periods of time, with more comprehensive patient data, for further analysis using a highly sensitive test his lab developed. 

The early findings are consistent with other work that has found the virus in the gut in people with at least one symptom of long Covid.

If persistent virus is causing or at least connected with some lingering Covid symptoms, it would make sense to test whether getting rid of that virus helps to relieve symptoms. Existing antivirals make this possible. The Food and Drug Administration has authorized Pfizer’s Paxlovid and Merck’s molnupiravir, and several other pills to treat acute infections are in clinical trials. Small studies already suggest that treatment with the drugs could be beneficial.

Larger trials are needed, however, to not only sort out whether the drugs work but also assess how long they should be taken and which patients might receive the most benefit. Such trials should already be underway.

At the moment, antivirals are being widely prescribed to vaccinated and unvaccinated Americans alike as part of the federal government’s test-to-treat program. As of June 12, more than 1.3 million courses of Paxlovid had been given out. Yet, perplexingly, there has been no effort to track whether the pills help minimize or prevent long-term symptoms.

Even the drug makers seem uninterested in testing the possibility. Steve Deeks, an HIV expert at the University of California, San Francisco, says that when he knocks on the doors of his industry partners to ask for drugs to use in long-Covid studies, he gets pushback. Companies agree the problem is serious, but wonder how he plans to assess a treatment’s effectiveness without having any validated measures of patient improvement. “There’s no way to really engage industry,” Deeks says. “This is a big problem.”

The longer it takes to find answers, the worse off patients will be. People desperate for help with their symptoms could fall prey to the kind of pseudoscience that has driven people to try useless, even harmful treatments for basic Covid. More long-Covid patients will experience deteriorating mental health, or even contemplate suicide.

Viral persistence isn’t the only theory worth exploring. Some scientists are studying whether Covid can cause blood clotting issues that lead to widespread damage in the body, while others believe the problem is that the immune system stays on high alert long after the infection fades.

But the viral persistence hypothesis is one that researchers have ample tools to investigate. They should be doing all they can to look for answers.

More From Bloomberg Opinion:

• Long Covid Is Showing Up in the Employment Data: Justin Fox

• Australia’s Early Flu Shows Americans Need Shots: Lisa Jarvis

• US Monkeypox Response Repeats Errors of Covid: Danzig & Lawler

This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.

Lisa Jarvis is a Bloomberg Opinion columnist covering biotech, health care and the pharmaceutical industry. Previously, she was executive editor of Chemical & Engineering News.

More stories like this are available on bloomberg.com/opinion

©2022 Bloomberg L.P.

Loading...